Halozyme Reports Fourth Quarter And Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c
February 29, 2016 4:07 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.03, $0.11 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $42.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $110-125 million, versus the consensus of... More
